Editors' Desk
-
Securing Biotech Funding When Economies Get Wild
6/12/2020
There’s disruption on the startup biotech money trail. Navigating it requires a pliable strategy. Here, multi-time founder and investor Bert Liang shares insight on raising funds during volatile times.
-
A New Cost Paradigm For CAR Cell Therapies?
6/12/2020
Hear from Acepodia CEO Sonny Hsiao about his company's claims that its proprietary approach to conjugating novel natural killer cells could reduce the cost of cellular therapeutics.
-
COVID-19 & The Virtual Trial Rush: Front-Line Insights
5/19/2020
The COVID-19 pandemic caught many sponsor companies and sites unprepared. Clinical trial participants were told to stay home for their own safety and to relieve the burden on site personnel. For companies that had millions invested in trials that required data from those patients, panic set in and the rush was on for new technology solutions.
-
Is Biopharma’s Response To Coronavirus Off The Mark?
3/4/2020
As biopharmas aplenty race to develop a vaccine, CureLab’s Alex Shneider says an incorrect approach risks turning the currently insignificant coronavirus threat into a deadly pandemic. He suggests that we instead focus on the development of adjuvants and immunostimulants to protect the elderly.
-
New U.S And Canadian Facilities Boosting Biologics Capacity
4/13/2018
Biopharma executives have warned they need more biologics development and manufacturing capacities, particularly in North America. They haven’t been howling at the moon. Four announcements – within two days of each other – offer a sign of relief. And Amgen has provided Outsourced Pharma with its first public estimate of costs for one of those facilities.
-
A Glimpse Into Thailand’s Ongoing Life Sciences Transformation
5/18/2017
During my visit to Thailand, I was privy, not only to the particularly innovative research goals being pursued, but also to a number of challenges the country has recognized and hopes to address within the next few years to encourage a stronger, more diverse industry.
-
What Thailand Revealed About U.S. Pharma R&D
5/16/2017
A few weeks ago, I was invited by the Thailand Board of Investment to attend a media trip to learn about the country’s budding life sciences industry. Entering Thailand, a country in which the government is pushing more investment and education in the sciences, was even more striking and meaningful to me given the current scientific climate in the U.S.
-
Top 5 Biosimilar Developments Of 2016
12/29/2016
In the spirit of this list-making season, I compiled what I thought were the five most important biosimilar-related triumphs in the past year. Many of these events were widely covered by the media and will play an influential role in how the biosimilar industry unfolds through 2017 and beyond.
-
Are You The Future of Pharmaceutical Development?
12/27/2016
Pfizer's Bernie Huyghe and ADC Therapeutics' Michael Mulkerrin get bushwhacked with this question in a public forum. Their open replies will help each one of you to your own personal assessment. Be prepared for some soul searching.
-
The Case For Moving The EMA To Ireland
12/13/2016
Relocating an organization as large as the EMA, which employs upwards of 1,000 people in London, will be no easy feat. As such, IDA Ireland, an agency that supports companies in Ireland and promotes foreign direct investments in the country, is working to compile information on why Ireland would be a good location for the EMA.